Zilsart
Generic Name
Losartan Potassium
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| zilsart 40 mg tablet | ৳ 12.00 | ৳ 120.00 |
Description
Overview of the medicine
Zilsart (Losartan Potassium) is an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension), reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, and treat kidney disease in patients with type 2 diabetes and high blood pressure.
Uses & Indications
Dosage
Adults
For hypertension: Initial dose 50 mg orally once daily. The dose can be increased to 100 mg once daily. For diabetic nephropathy: Initial dose 50 mg orally once daily, may be increased to 100 mg once daily based on blood pressure response.
Elderly
No initial dosage adjustment is usually necessary for elderly patients, but starting with a lower dose (e.g., 25 mg) may be considered, especially if volume depleted.
Renal_impairment
No initial dosage adjustment is necessary for patients with mild to moderate renal impairment. For patients with severe renal impairment (creatinine clearance <30 mL/min/1.73 m²), a lower starting dose (e.g., 25 mg once daily) may be considered.
How to Take
Zilsart tablets can be taken orally with or without food. It is recommended to take the tablet at the same time each day.
Mechanism of Action
Losartan selectively blocks the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). This blockade inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation, decreased aldosterone secretion, reduced sodium and water reabsorption, and ultimately a reduction in blood pressure.
Pharmacokinetics
Onset
Onset of antihypertensive effect is within approximately 6 hours, with full effect achieved within 3-6 weeks of therapy.
Excretion
Approximately 35% of the dose is excreted in the urine and approximately 58% in the feces via bile.
Half life
The terminal half-life of losartan is approximately 2 hours, and its active metabolite (E-3174) is about 6-9 hours.
Absorption
Well absorbed from the gastrointestinal tract, but undergoes significant first-pass metabolism. Oral bioavailability is approximately 33%. Peak plasma concentrations of losartan are reached in about 1 hour, and for its active metabolite (E-3174) in 3-4 hours.
Metabolism
Undergoes extensive first-pass metabolism by cytochrome P450 enzymes (CYP2C9 and CYP3A4) to form an active carboxylic acid metabolite (E-3174), which is more potent than losartan, and other inactive metabolites.
Side Effects
Contraindications
- Hypersensitivity to Losartan or any component of the formulation.
- Pregnancy (especially second and third trimesters) due to risk of fetal toxicity.
- Concomitant use with aliskiren in patients with diabetes mellitus.
Drug Interactions
Lithium
Concurrent use may increase serum lithium concentrations and lead to lithium toxicity. Monitor serum lithium levels carefully.
Other antihypertensive agents
May have additive hypotensive effects.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs), including selective COX-2 inhibitors
May reduce the antihypertensive effect of losartan and can lead to deterioration of renal function, including possible acute renal failure, particularly in elderly or volume-depleted patients.
Potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride) or potassium supplements
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
Limited data are available regarding overdose in humans. The most likely manifestations of overdose would be hypotension and tachycardia; bradycardia could occur from parasympathetic stimulation. Management involves symptomatic and supportive treatment. If ingestion is recent, induce emesis or perform gastric lavage. Hemodialysis is unlikely to remove losartan or its active metabolite.
Pregnancy & Lactation
Pregnancy Category D (2nd and 3rd trimesters). Use of ARBs during the second and third trimesters of pregnancy can cause injury and death to the developing fetus. Zilsart should be discontinued as soon as pregnancy is detected. It is not known whether losartan is excreted in human milk, but a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Side Effects
Contraindications
- Hypersensitivity to Losartan or any component of the formulation.
- Pregnancy (especially second and third trimesters) due to risk of fetal toxicity.
- Concomitant use with aliskiren in patients with diabetes mellitus.
Drug Interactions
Lithium
Concurrent use may increase serum lithium concentrations and lead to lithium toxicity. Monitor serum lithium levels carefully.
Other antihypertensive agents
May have additive hypotensive effects.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs), including selective COX-2 inhibitors
May reduce the antihypertensive effect of losartan and can lead to deterioration of renal function, including possible acute renal failure, particularly in elderly or volume-depleted patients.
Potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride) or potassium supplements
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
Limited data are available regarding overdose in humans. The most likely manifestations of overdose would be hypotension and tachycardia; bradycardia could occur from parasympathetic stimulation. Management involves symptomatic and supportive treatment. If ingestion is recent, induce emesis or perform gastric lavage. Hemodialysis is unlikely to remove losartan or its active metabolite.
Pregnancy & Lactation
Pregnancy Category D (2nd and 3rd trimesters). Use of ARBs during the second and third trimesters of pregnancy can cause injury and death to the developing fetus. Zilsart should be discontinued as soon as pregnancy is detected. It is not known whether losartan is excreted in human milk, but a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 to 36 months from the date of manufacture, specific details on packaging.
Availability
Available in pharmacies and hospitals nationwide
Approval Status
Approved by FDA and DGDA
Patent Status
Off-patent
WHO Essential Medicine
YesClinical Trials
Losartan has undergone extensive clinical trials demonstrating its efficacy and safety in treating hypertension, diabetic nephropathy, and reducing cardiovascular events. Key trials include the LIFE study (Losartan Intervention For Endpoint reduction in hypertension study) and the RENAAL study (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study).
Lab Monitoring
- Serum potassium levels (especially in patients with renal impairment or those on potassium-sparing diuretics).
- Renal function (creatinine, BUN) before initiation and periodically during treatment.
- Blood pressure monitoring regularly.
Doctor Notes
- Monitor blood pressure, renal function (creatinine, GFR), and serum potassium periodically.
- Counsel patients on the importance of adherence, especially for chronic conditions like hypertension.
- Caution when co-administering with NSAIDs or potassium-sparing diuretics.
- Avoid in pregnancy due to fetal toxicity.
Patient Guidelines
- Take Zilsart regularly as prescribed by your doctor, even if you feel well.
- Do not stop taking the medicine suddenly without consulting your doctor.
- Inform your doctor about all other medications, supplements, and herbal products you are taking.
- Avoid potassium-rich foods or potassium supplements unless advised by your doctor.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Zilsart may cause dizziness or lightheadedness, especially at the beginning of treatment or when changing dose. If you experience these symptoms, avoid driving or operating machinery.
Lifestyle Advice
- Adopt a healthy diet low in sodium and saturated fats.
- Engage in regular physical activity.
- Maintain a healthy weight.
- Limit alcohol consumption and avoid smoking.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Zilsart Brand
Other medicines available under the same brand name
